Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

50 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
AKT and cancer--is it all mTOR?
Rosen N, She QB. Rosen N, et al. Cancer Cell. 2006 Oct;10(4):254-6. doi: 10.1016/j.ccr.2006.10.001. Cancer Cell. 2006. PMID: 17045203
Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1.
Wang J, Ye Q, Cao Y, Guo Y, Huang X, Mi W, Liu S, Wang C, Yang HS, Zhou BP, Evers BM, She QB. Wang J, et al. Among authors: she qb. Nat Commun. 2017 Dec 20;8(1):2207. doi: 10.1038/s41467-017-02243-3. Nat Commun. 2017. PMID: 29263324 Free PMC article.
Models from experiments: combinatorial drug perturbations of cancer cells.
Nelander S, Wang W, Nilsson B, She QB, Pratilas C, Rosen N, Gennemark P, Sander C. Nelander S, et al. Mol Syst Biol. 2008;4:216. doi: 10.1038/msb.2008.53. Epub 2008 Sep 2. Mol Syst Biol. 2008. PMID: 18766176 Free PMC article.
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.
She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit DB, Rosen N. She QB, et al. Cancer Cell. 2010 Jul 13;18(1):39-51. doi: 10.1016/j.ccr.2010.05.023. Cancer Cell. 2010. PMID: 20609351 Free PMC article.
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
She QB, Gruvberger-Saal SK, Maurer M, Chen Y, Jumppanen M, Su T, Dendy M, Lau YK, Memeo L, Horlings HM, van de Vijver MJ, Isola J, Hibshoosh H, Rosen N, Parsons R, Saal LH. She QB, et al. BMC Cancer. 2016 Aug 2;16:587. doi: 10.1186/s12885-016-2609-2. BMC Cancer. 2016. PMID: 27484095 Free PMC article.
Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus.
Liu Y, Liu F, Yu H, Zhao X, Sashida G, Deblasio A, Harr M, She QB, Chen Z, Lin HK, Di Giandomenico S, Elf SE, Yang Y, Miyata Y, Huang G, Menendez S, Mellinghoff IK, Rosen N, Pandolfi PP, Hedvat CV, Nimer SD. Liu Y, et al. Sci Signal. 2012 Oct 23;5(247):ra77. doi: 10.1126/scisignal.2003199. Sci Signal. 2012. PMID: 23092893 Free PMC article.
Genomic complexity and AKT dependence in serous ovarian cancer.
Hanrahan AJ, Schultz N, Westfal ML, Sakr RA, Giri DD, Scarperi S, Janakiraman M, Olvera N, Stevens EV, She QB, Aghajanian C, King TA, Stanchina Ed, Spriggs DR, Heguy A, Taylor BS, Sander C, Rosen N, Levine DA, Solit DB. Hanrahan AJ, et al. Cancer Discov. 2012 Jan;2(1):56-67. doi: 10.1158/2159-8290.CD-11-0170. Cancer Discov. 2012. PMID: 22328975 Free PMC article.
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N. Halilovic E, et al. Cancer Res. 2010 Sep 1;70(17):6804-14. doi: 10.1158/0008-5472.CAN-10-0409. Epub 2010 Aug 10. Cancer Res. 2010. PMID: 20699365 Free PMC article.
50 results
Jump to page
Feedback